In Vivo Imaging, Dosimetry and Technology Transfer

体内成像、剂量测定和技术转让

• 批准号: 8374944
• 负责人: Brian W. Pogue
• 金额: $ 23.66万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-08-09 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8374944
• 关键词: Analysis of Variance; Area; Cancer Model; Clinical; Clinical Research; Clinical Trials; Collaborations; Communication; Communities; Complex; Computer software; Data; Data Analyses; Development; Diffuse; Dose; Education; Ensure; Epidermal Growth Factor Receptor; Equilibrium; Equipment; Feedback; Financial compensation; Functional Imaging; Funding; Future; Goals; Human Resources; Hybrids; Image; Imaging Device; Industry; Institution; Internet; Knowledge; Lead; Legal patent; Light; Location; Magnetic Resonance Imaging; Malignant neoplasm of pancreas; Maps; Measurement; Measures; Methods; Modeling; Molecular; Monitor; Optical Tomography; Organ; Pharmaceutical Preparations; Photosensitizing Agents; Physiological; Positron-Emission Tomography; Pre-Clinical Model; Principal Investigator; Protein Structure Initiative; Proteins; Public Health; Recommendation; Reporter; Research; Resolution; Resources; Role; Schedule; Services; Singlet Oxygen; Site; Skin Cancer; Software Tools; Solutions; System; Technology; Technology Transfer; Testing; Time; Training; Translating; Translations; Treatment outcome; United States National Institutes of Health; Update; Variant; Vascular Endothelial Growth Factors; Visualization software; Work; base; cancer therapy; commercialization; design; dosimetry; experience; fluorescence imaging; imaging modality; improved; in vivo; instrumentation; knowledge base; meetings; member; molecular imaging; optical imaging; physical science; pre-clinical; programs; public-private partnership; research study; response; success; technology development; tomography; tool; treatment planning; user-friendly

pRnvinpn Core C has both research and service goals, with the overall theme of developing new and useful imaging and dosimetry approaches to help optimize PDT in preclinical models and clinical studies. The systems used by each project vary considerably,yet the file systems, data analysis, planning and dosimetry concepts can be centralized and inter-project communication in this area can significantly enhance the quality of research. The core is subdivided into four distinct aims, including (!) Structural and functional imaging and dosimetry; (ii) Photophysical imaging/monitoring in vivo; (iii) Molecular imaging in vivo; and (iv)Technology translation. These aims all work with the projects to ensure that developments from one project may assist in another, and that methods, doses, image files, and developed softwaregets used to the highest potential. There are specific areas in structural dosimetry which will be developed including optical imaging translation, clinical dosimetry, mesh creation and light modeling tools, and visualization software. The core will assist Projects 1 and 2 in establishing functioning dosimetry system for all clinical trials, complete with instrumentation to measure the light and PS, as well as treatment planning software which has the capabilities to adapt the light doses in real time. The photophysical dosimetry will involve development of a specialized high resolution fluorescence imaging system for skin cancer treatment mapping. The variance of PS concentration will be studied in both skin and pancreatic cancer models, as well as installation and testing of singletoxygen dosimetry in collaboration with PSI. The recent developments in molecular imaging will be extended into imaging in vivo, and be used to quantify the expression EGFR, VEGF levels, and expression of other key proteins in vivo. Integrated optical tomography with MRI, US, CT will be used to study these with high image resolution. The final aim tackles the complex issue of technology transfer, and when to spend time on patenting and shareware distribution of technology. We have partners in several companies, and these will be leveraged to help guide our next steps, as well as working through the technology transfer offices of each institution, and the CIMIT center at MGH to fulfill the NIH Roadmap goals of private public partnerships. The core will administer and update a share ware site for distribution of software tools and dosimetry designs, for systems, which do not have immediate commercial potential, yet would benefit the field of PDT in general by distribution to other academic centers. The core is centered at Dartmouth and MGH, as these sites have been the locus of technology developments in the past funding period, yet the key personnel and collaborators at each site have planned bi-annual meetings and more often weekly meetings planned during clinical trials. Enhanced file transfer and customized software tools will improve the interactions planned and make this core significantly improve the quality of research at each of the project sites. The potential benefits to public health that this Core provides is in the form of new dosimetry and imaging tools for better treatment outcomes and initiating commercialization of research in the Program in partnership with industry.

pRnvinpn Core C 具有研究和服务目标，总体主题是开发新的、有用的成像和 剂量测定方法有助于优化临床前模型和临床研究中的 PDT。使用的系统 每个项目差异很大，但文件系统、数据分析、规划和剂量测定概念可以 该领域的集中和项目间交流可以显着提高研究质量。这 核心分为四个不同的目标，包括（！）结构和功能成像以及剂量测定； (二) 体内光物理成像/监测； (iii) 体内分子成像； (iv)技术翻译。 这些目标都与项目相配合，以确保一个项目的开发可以帮助另一个项目，并且 方法、剂量、图像文件和开发的软件都能发挥最大潜力。有 将开发的结构剂量测定的特定领域包括光学成像翻译、临床 剂量测定、网格创建和光建模工具以及可视化软件。核心将协助项目1 2 为所有临床试验建立有效的剂量测定系统，并配备仪器以 测量光线和 PS，以及具有适应光线功能的治疗计划软件 实时剂量。光物理剂量测定将涉及开发专门的高分辨率 用于皮肤癌治疗绘图的荧光成像系统。 PS浓度的方差为 研究了皮肤癌和胰腺癌模型，以及单线氧气的安装和测试 与 PSI 合作进行剂量测定。分子成像的最新发展将扩展到 体内成像，并用于量化 EGFR、VEGF 水平以及其他关键蛋白的表达 体内的蛋白质。结合 MRI、US、CT 的集成光学断层扫描将用于高图像研究 解决。最终目标解决技术转让的复杂问题，以及何时花时间 技术专利申请和共享软件分发。我们在多家公司有合作伙伴，这些将是 用于帮助指导我们的后续步骤，以及通过每个国家的技术转让办公室开展工作 机构和 MGH 的 CIMIT 中心，以实现 NIH 私营公共伙伴关系路线图目标。这 核心将管理和更新一个共享软件站点，用于分发软件工具和剂量测定设计， 系统，虽然不具有直接的商业潜力，但总体上将使 PDT 领域受益 分发给其他学术中心。核心以达特茅斯和 MGH 为中心，因为这些站点有 是过去资助期间技术发展的焦点，但关键人员和合作者 每个中心都计划每两年举行一次会议，并且在临床试验期间更经常计划每周举行一次会议。 增强的文件传输和定制的软件工具将改善计划的交互并使这一核心 显着提高每个项目地点的研究质量。对公众的潜在好处 该核心提供的健康以新的剂量测定和成像工具的形式提供，以实现更好的治疗结果 并与工业界合作启动该计划研究的商业化。